Avinger, Inc. (AVGR)

Avinger Announces Treatment of First Patients Globally With Next Generation Pantheris

REDWOOD CITY, Calif., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), announced that Arne Schwindt, M.D., a vascular surgeon at St. Franziskus Hospital in Münster, Germany, has successfully treated the first seven patients with the next generation Pantheris Lumivascular atherectomy system. Dr. Schwindt, an experienced operator of Lumivascular technology, used the next generation Pantheris to treat seven separate patients with a variety of lesion types, including in-stent restenosis (ISR), a calcified lesion, and a chronic total occlusion, in arteries above and below the knee.

The next generation Pantheris design includes a simplified single balloon system for both apposition of the device and occlusion of blood flow, a stiffer shaft for increased pushability, a more robust nose cone with the option for more tissue storage capacity, and an enhanced cutter design. This device is available in limited supply for commercial sale in the EU; it is not available commercially in the United States at this time.

In each of the seven cases, Pantheris performed as intended, and Dr. Schwindt made note of the design features that enabled significant performance improvements as compared to previous versions of the device, including better directional control of the cutter blade for more precise atherectomy. Dr. Schwindt also provided feedback about the increased maneuverability of the system, greater tissue capture versus the similarly sized previous version of Pantheris, increased efficiency and ease of cleaning the device between insertions, and high quality imaging in a variety of vessel diameters.

In commenting on his initial cases, which included a patient with a total occlusion of a stent and multiple below-the-knee lesions, Dr. Schwindt noted, “Next generation Pantheris with real-time image guidance enabled me to see the stent struts and precisely target and remove substantial amounts of tissue that had grown into the stent. In two patients the disease extended below the knee. Image-guided atherectomy with the next generation Pantheris made it possible to precisely target and remove atherosclerotic plaque in this region while conserving the deep wall components and thus reducing the risk of perforations in these small vessels. The angiographic outcome was excellent.”

“We are thrilled that Dr. Schwindt was the first in the world to use the next generation of Pantheris, especially given the excellent outcomes for patients in this initial experience with the device,” said Jeff Soinski, Avinger’s president and CEO. “These cases helped to validate the enhancements we have made to Pantheris, both in terms of performance and reliability. We believe the initial results generated by Dr. Schwindt with the device represent an important step both for Avinger and for the evolution of treatment for patients with PAD.”

Atherectomy is a minimally invasive treatment for PAD in which a catheter-based device is used to remove plaque from a blood vessel. Lumivascular technology allows physicians, for the first time ever, to see from inside the artery during an atherectomy procedure by using an imaging modality called optical coherence tomography, or OCT, that is displayed on Avinger’s proprietary Lightbox console. Physicians performing atherectomy with other devices must rely solely on X-ray as well as tactile feedback to guide their interventions while treating complicated arterial disease. With the Lumivascular approach, physicians can more accurately navigate their devices and treat PAD lesions, thanks to the real-time OCT images generated from inside the artery, without exposing healthcare workers and patients to the negative effects of ionizing radiation.

About Avinger, Inc.
Avinger is a commercial-stage medical device company that designs and develops the first-ever image-guided, catheter-based system that diagnoses and treats patients with peripheral artery disease (PAD). Avinger is dedicated to radically changing the way vascular disease is treated through its Lumivascular platform, which currently consists of the Lightbox imaging console, the Ocelot family of chronic total occlusion (CTO) catheters, and the PantherisÒ family of atherectomy devices. Avinger is based in Redwood City, California. For more information, please visit www.avinger.com.  

gnadenlos abgestürzt das Teil,aber interessant,jetzt kommen die ersten positiven News,Aktie beinaHE GESCHENKT,Medizintechnik vom Feinstgen ?

MFG
Chali  

günstig, begründe mal bitte warum ?


günstig wäre, wenn Pipeline umsonst und Notierung unter Netcash, isr dem aber nicht so!!  

das Ding wurde aber richtig verprügelt nach dem R/S und vorbörslich schon wieder fett im Minus.

Hmmm add it to WL  

Schauen wir mal was passiert!  

kleinen Pos drin.  

Scheint den Boden erreicht zu haben - enormes Volumen in New York am Freitag. Könnte Montag 20% zulegen. Trotzdem bleibe ich hier sehr vorsichtig.

Meine BIO Watchlist...
TGTX (mein persönlicher Blockbuster)
XON
REPH (sollte kommende Woche hochgehen)
CFRX
AFMD (long bis 2019 - tolle Pipeline)
TRCX (Boden gefunden - long)  

Hallo stksat|228858,

stimme Dir zu, sehr riskanter Wert. Habe hier auch nur eine kleine Position stehen. Heute nach AH sollen noch Quartalszahlen kommen.

Meine größte Bios Pos. steht aktuell bei MBRX mit 13k Shares. Die haben eine hervorragende Pipeline und der Start von 3 Trial dieses Jahr steht bevor, davon 2 noch diesen Monat,

https://www.benzinga.com/general/biotech/18/03/...a-candidate-could-b  

Franzlsepp - Danke dir, Moleculin Biotech werde ich mir gleich näher ansehen. Bin erst seit einem Jahr in diesem BIO Markt (sonst eher Rohstoffe und alternative Energien) investiert und finde das Feld sehr spannend. Mal sehen was hier diese Woche passiert. Pre Market sieht gut aus. Die werden jedoch auf alle Fälle wieder Mittel (Kapitalerhöhung) zeitnah benötigen.
 

@stksat|228858, du solltest eine BM von mir bekommen haben.  

warum KE? Bitte belegen-danke-  

ordentlichen Knall (Short Squeeze) heute geben, 1.50 Break notwendig.  

Platz nach oben ist jede Menge vorhanden...  

Hallo Monaco, hatte nur einen Blick auf Zahlen im link geworfen (bis September 17) und die "Cash-Burn-Rate" empfand ich als extrem vs. Umsätzen und Net Income. Außerdem verliert man durch so einen extremen R/S die großen Anleger.

Das Produkt finde ich extrem spannend und hatte heute morgen auch nachgekauft.

http://quotes.wsj.com/AVGR/financials  

Hast recht Monaco - 1,68 ist die nächste große Hürde in Richtung 2,- Dollar...  

Denke wir gehen noch höher  

 

 

Das das Handelsvolumen steigt und das ein Insider Aktien gekauft hat.
https://www.dispatchtribunal.com/2018/03/05/...cquires-50-shares.html  

 

Watchlist  

gelegt, geht schonmal etwas rauf  

am St. Franziskus - Krankenhaus in Münster.  

ist ja schon da, warten jetzt auf FDA.  

https://www.medgadget.com/2018/04/...-ceo-president-jeff-soinski.html